Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial
Ryusaburo Mori, Shigeru Honda, Fumi Gomi, Akitaka Tsujikawa, Hideki Koizumi, Haruka Ochi, Shino Ohsawa, Annabelle A. Okada, on behalf of TENAYA and LUCERNE Investigators
Topics & Concepts
AfliberceptMedicineMacular degenerationSubgroup analysisAdverse effectClinical endpointRandomized controlled trialVisual acuityClinical trialDosingOphthalmologyInternal medicineConfidence intervalSurgeryBevacizumabChemotherapyRetinal Diseases and TreatmentsOphthalmology and Visual Impairment StudiesRetinal Imaging and Analysis